ACP
AKRO

Acuta Capital Partners’s Akero Therapeutics AKRO Stock Holding History

Acuta Capital Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,772
Closed -$1.06M – 29
2025
Q2 		$1.06M Buy
+19,772
New +$898K 1.47% 19

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's AKRO Position: Q3 2025 in Review

Acuta Capital Partners sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 19,772 shares — an estimated $1.06M sold.

Acuta Capital Partners first reported a position in AKRO in Q2 2025 and held it in 1 quarter. The position peaked at $1.06M in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Acuta Capital Partners reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 19,772 Akero Therapeutics shares in Q3 2025, an estimated $1.06M.
  • Acuta Capital Partners first reported a position in Akero Therapeutics in Q2 2025 and held it in 1 quarter.
  • Acuta Capital Partners's Akero Therapeutics position peaked at $1.06M in Q2 2025.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Acuta Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.